2022
Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial
Wang SY, Hanna JM, Gongal P, Onuma O, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. American Heart Journal 2022, 254: 30-34. PMID: 35932912, PMCID: PMC10908340, DOI: 10.1016/j.ahj.2022.07.006.Peer-Reviewed Original ResearchConceptsDiastolic hypertensionSystolic hypertensionAntihypertensive agentsSecondary analysisPrevent Heart Attack TrialBroad treatment recommendationsDifferent antihypertensive agentsUse of chlorthalidoneLipid-lowering treatmentHeart Attack TrialCoronary heart diseaseCause mortalityPrimary outcomeAttack TrialALLHAT trialHeart diseaseTreatment recommendationsHypertensionPatientsTrialsAntihypertensivesAmlodipineLisinoprilStrokeAgents
2003
Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial
Lampert R, Ickovics JR, Viscoli CJ, Horwitz RI, Lee FA. Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial. The American Journal Of Cardiology 2003, 91: 137-142. PMID: 12521623, DOI: 10.1016/s0002-9149(02)03098-9.Peer-Reviewed Original ResearchConceptsBeta-Blocker Heart Attack TrialAcute myocardial infarctionHeart rate variabilityPlacebo-treated patientsHeart Attack TrialMyocardial infarctionEffect of propranololBeta blockersAttack TrialDepressed heart rate variabilityRate variabilityRecovery of HRVLF/HF ratioPropranolol-treated patientsWeeks of treatmentHF ratioHigh-frequency powerPropranolol therapyPropranolol treatmentSympathetic predominanceAutonomic toneParasympathetic toneSympathovagal balanceImproved outcomesSudden death
1997
Functional recovery after myocardial infarction in men: the independent effects of social class.
Ickovics JR, Viscoli CM, Horwitz RI. Functional recovery after myocardial infarction in men: the independent effects of social class. Annals Of Internal Medicine 1997, 127: 518-25. PMID: 9313019, DOI: 10.7326/0003-4819-127-7-199710010-00003.Peer-Reviewed Original ResearchConceptsBeta-Blocker Heart Attack TrialHeart Attack TrialMyocardial infarctionFunctional recoveryAttack TrialNew York Heart Association functional classPsychosocial factorsYork Heart Association functional classFunctional status 1 yearDouble-blind clinical trialCardiovascular-related illnessesPertinent prognostic factorsAcute myocardial infarctionIndependent effectsYears of agePrimary outcomePrognostic factorsClinical outcomesFunctional statusProspective dataClinical trialsInfarctionHigher social classMen 29Baseline assessment
1996
Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
Horwitz R, Singer B, Makuch R, Viscoli C. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Journal Of Clinical Epidemiology 1996, 49: 395-400. PMID: 8621989, DOI: 10.1016/0895-4356(95)00058-5.Peer-Reviewed Original ResearchConceptsClinical inquiryBeta-Blocker Heart Attack TrialCoronary artery surgeryHeart Attack TrialSubgroup of patientsArtery surgeryAspirin useCoronary surgeryMulticenter RCTClinical featuresAttack TrialClinical centersClinical conditionsTreatment groupsPatientsBenefit of propranololClinical decisionTrial resultsHeterogeneous groupPropranololRCTsSurgeryTreatmentTrialsOverall benefit
1993
Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness.
Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Annals Of Internal Medicine 1993, 118: 99-105. PMID: 8416325, DOI: 10.7326/0003-4819-118-2-199301150-00004.Peer-Reviewed Original ResearchConceptsBeta-blocker therapyClinical courseVital statusMyocardial infarctionLong-term beneficial effectsPlacebo-controlled trialRecurrent ischemic eventsInitiation of therapyCongestive heart failureHeart Attack TrialLong-term therapeutic benefitHeterogeneous clinical courseYears of ageLong-term effectivenessEligible patientsSevere comorbiditiesBeta blockersIschemic eventsHeart failureTrial entryAttack TrialClinical centersSubsequent riskWomen 30High risk
1990
Treatment adherence and risk of death after a myocardial infarction
Horwitz RI, Viscoli CM, Donaldson R, Murray C, Ransohoff D, Horwitz R, Berkman L, Horwitz S, Ransohoff D, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. The Lancet 1990, 336: 542-545. PMID: 1975045, DOI: 10.1016/0140-6736(90)92095-y.Peer-Reviewed Original ResearchConceptsRisk of deathTreatment adherenceMyocardial infarctionPoor adherersBeta-Blocker Heart Attack TrialPost-infarction mortalityHeart Attack TrialGood adherersTreatment regimenAttack TrialClinical severitySociodemographic featuresInfarctionAdherersAdherenceDeathMortalityRiskSeverityPlaceboRegimenSmokingPatientsPropranololTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply